SCIENCE@home

Clinical targeting recombinant immunotoxins for cancer therapy

M. Li,Zeng-Shan Liu,Xilin Liu,Qi Hui,Shi-Ying Lu,Lin-Lin Qu,Yansong Li,Yu Zhou,H. Ren,P. Hu

Published 2017 in OncoTargets and Therapy

ABSTRACT

Recombinant immunotoxins (RITs) are proteins that contain a toxin fused to an antibody or small molecules and are constructed by the genetic engineering technique. RITs can bind to and be internalized by cells and kill cancerous or non-cancerous cells by inhibiting protein synthesis. A wide variety of RITs have been tested against different cancers in cell culture, xenograft models, and human patients during the past several decades. RITs have shown activity in therapy of several kinds of cancers, but different levels of side effects, mainly related to vascular leak syndrome, were also observed in the treated patients. High immunogenicity of RITs limited their long-term or repeat applications in clinical cases. Recent advances in the design of immunotoxins, such as humanization of antibody fragment, PEGylation, and modification of human B- and T-cell epitopes, are overcoming the above mentioned problems, which predict the use of these immunotoxins as a potential therapeutic method to treat cancer patients.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-100 of 210 references · Page 1 of 3

123
Next

CITED BY

Showing 1-40 of 40 citing papers · Page 1 of 1